| Name: | Acarbose EP Impurity B |
| Catalogue No. | VL5070003 |
| CAS No. | N/A |
| Molecular Formula | C26H43NO17 |
| Molecular Weight | 641.63 |
| Status | Under Development |
| IUPAC Name | (1S,2S,3R,6S)-6-(((2R,3S,4S,5R,6R)-6-(((2R,3S,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-(((1R,4S,5S,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)cyclohex-2-en-1-yl)oxy)tetrahydro-2H-pyran-3-yl)oxy)-4,5-dihydroxy-2-methyltetrahydro-2H-pyran-3-yl)amino)-4-(hydroxymethyl)cyclohex-4-ene-1,2,3-triol |
| Description | Acarbose EP Impurity B is an impurity detected in Acarbose that is used in the treatment of non-insulin-dependent or insulin-dependent diabetes. It acts by delaying the production of monosaccharides by inhibiting the a-glucosidases. |
| References | Wang, Ya-Jun, et al. “Analysis and Determination of Anti-Diabetes Drug Acarbose and Its Structural Analogs.” Current Pharmaceutical Analysis, vol. 7, no. 1, Feb. 2011, pp. 12–20, https://doi.org/10.2174/157341211794708721. Clissold, Stephen P., and Clive Edwards. “Acarbose.” Drugs, vol. 35, no. 3, Mar. 1988, pp. 214–43, https://doi.org/10.2165/00003495-198835030-00003. |
